Logo
x

Search

Subscribe Now

Fails

AstraZeneca's Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19

AstraZeneca's Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19

  • April 12, 2021
Roche's Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary Endpoints in P-III REMDACTA Study for Patients with Severe COVID-19 Pneumonia

Roche's Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary Endpoints in P-III REMDACTA Study for Patients with Sev...

  • March 11, 2021
AstraZeneca's Imfinzi Fails to Meet its Primary Endpoints in P-III KESTREL Study

AstraZeneca's Imfinzi Fails to Meet its Primary Endpoints in P-III KESTREL Study

  • February 8, 2021
Biohaven's Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer's Disease

Biohaven's Troriluzole Fails to Meet its Co-Primary Endpoints in P-II/III Study for Alzheimer's Disease

  • January 20, 2021
Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

  • August 25, 2020
Roche's Actemra/RoActemra (tocilizumab) Fails to Meet the Primary Endpoint in P-III COVACTA Study for Patients with COVID-19 Associated Pneumonia

Roche's Actemra/RoActemra (tocilizumab) Fails to Meet the Primary Endpoint in P-III COVACTA Study for Patients with COVID-19 Assoc...

  • July 29, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.